(Total Views: 533)
Posted On: 06/11/2024 4:34:56 PM
Post# of 148863
similar efficacy can result in approval
thats great news!!!
so donanemab has similar efficacy as leqembi, as well as some deaths in the trial, and still gets approved. either leronlimab now has much more of a fighting chance to get approval or the system is so corrupt that only BP drugs are attended to and considered for reason of profits and profits only, even if the drugs are making NO STRIDES TOWARDS EFFICACY.
which should mean that if leronlimab has similar efficacy and far less - all the way to zero - side effects, it HAS to be approved? 4 out of 5 logical citizens say yes.
and didnt a death in our trial result in a 2 year hold? why wasnt donanemab put on the same type of hold? i know the answer.
"what is unique about this one - doanemab - is that since the results on efficacy and safety were so similar to Leqembi,"
https://www.medicalnewstoday.com/articles/fda...-donanemab
thats great news!!!
so donanemab has similar efficacy as leqembi, as well as some deaths in the trial, and still gets approved. either leronlimab now has much more of a fighting chance to get approval or the system is so corrupt that only BP drugs are attended to and considered for reason of profits and profits only, even if the drugs are making NO STRIDES TOWARDS EFFICACY.
which should mean that if leronlimab has similar efficacy and far less - all the way to zero - side effects, it HAS to be approved? 4 out of 5 logical citizens say yes.
and didnt a death in our trial result in a 2 year hold? why wasnt donanemab put on the same type of hold? i know the answer.
"what is unique about this one - doanemab - is that since the results on efficacy and safety were so similar to Leqembi,"
https://www.medicalnewstoday.com/articles/fda...-donanemab
Quote:
FDA panel recommends Eli Lilly's early-stage Alzheimer's treatment, donanemab, for approval, despite safety concerns and deaths reported during the trial.
* Lilly's results showed a 35% reduction in progress of the disease in 18 months.
The only other drug on the market currently is Eisai and Biogen's (BIIB) Leqembi, which showed a 27% decline in progression of the disease in patients who used it for 18 months.
https://www.yahoo.com/finance/news/fda-panel-...20037.html
________________
An $875 sp company.
Gotta like how they don't call it 65% or 73% failures, for govt. $3.5b yearly cost.
Leronlimab comparison will straighten that out.
Shall see.....
Investors Hangout: https://investorshangout.com/post/newpost/605...z8csQeb5XK
(6)
(0)Scroll down for more posts ▼
